About: Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.75 (-5.41%)
ELTX NASDAQ Elicio Therapeutics Inc.
Elicio Therapeutics Inc. share price
Atividade de preço de ELTX
Último preço
$ 1,750
Variação (24h)
-0,10 USD (5,41%)
Volume
135.90K
Volume (média 4 sem.)
-
Abertura
$ 1,82
Variação do dia
$ 1,75 - $ 1,89
Fechamento anterior
$ 1,85
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
ELTX price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals